Molnupiravir

Long COVID symptoms can improve, but their resolution is slow and imperfect

Retrieved on: 
Dimanche, septembre 3, 2023
People, Taste, Infection, Learning, White House, KN95, Molnupiravir, Fatigue, Omicron, Depression, COVID, Diabetes, Vaccination, Mitochondrion, Anosmia, SARS-CoV-2, Stroke, Quality of life, PET, POTS, Nirmatrelvir/ritonavir, Brain, Research, Cell, Veteran, White, Dementia, Man, Patient, Metformin, Risk, Lethargy, N95, United Kingdom, Longevity, Death, Disease, Pharmaceutical industry, Vaccine

Shortness of breath, brain fog, lethargy and tiredness, loss of smell or taste are common features of long COVID, as is the development of new conditions such as diabetes, heart disease, stroke, depression and dementia.

Key Points: 
  • Shortness of breath, brain fog, lethargy and tiredness, loss of smell or taste are common features of long COVID, as is the development of new conditions such as diabetes, heart disease, stroke, depression and dementia.
  • Read more:
    When does COVID become long COVID?
  • This and other recently published studies on long COVID show that while symptoms do resolve in many people, their resolution is slow and imperfect.

What did the study find?

    • The researchers followed 139,000 people with COVID and almost six million uninfected controls for two years, tracking deaths, hospitalisations and 80 long-term impacts of COVID, categorised into ten organ systems.
    • After two years, this “hospitalised” group remained at increased risk of 50 conditions.
    • This included a risk of clots and blood disorders, lung disease, fatigue, gut disorders, muscle and joint disorders and diabetes.

Findings from other recent research were similar

    • The risk of death was concentrated in the first six months after infection.
    • A third, not yet peer-reviewed and smaller cohort study of 341 people with long COVID from Spain, found only 7.6% of them recovered at two years.
    • An Australian (not yet peer-reviewed) study followed 31 people who developed long COVID and 31 matched controls who recovered from COVID for two years.
    • Finally, a recent whole-body positron emission tomography (PET) imaging and biopsy study showed prolonged tissue level immune-activation and viral persistence in the gut for up to a remarkable two years after COVID.

These studies have some limitations

    • It’s important to note the observational studies have some inherent limitations.
    • The US veterans cohort studied by Al-Aly is nearly 90% men, with an average age of 61 years, which is different to groups most at risk of long COVID.

We still don’t have treatments for long COVID

    • In July 2023, the White House established the Office of Long COVID Research and Practice.
    • Two randomised trials are testing whether the antiviral nirmatrelvir-ritonavir (Paxlovid) can treat long COVID are currently recruiting patients.

But it’s still important to prevent COVID (re)infections

    • Taken together, these studies on the longevity of long COVID add substantially to the case to fast-track the development of interventions and therapies to prevent and/or cure the condition.
    • In the meantime, it’s crucially important to prevent (re)infections in the first place to reduce the future burden of long COVID, already estimated to be greater than 65 million people globally.
    • If you suspect you have long COVID, discuss this with your GP, who may refer you to specialised services or multidisciplinary care.

Latham BioPharm Group Awarded Grant to Develop a Global Health Cost Model Platform

Retrieved on: 
Mercredi, juin 21, 2023
Government, Economics, COVID-19, Bill, Molnupiravir, API, Patient, Risk and strategic consulting, LBG, Public, Pharmaceutical industry, Sia Partners

BALTIMORE, June 21, 2023 /PRNewswire/ -- Latham BioPharm Group (LBG), part of Sia Partners, has been awarded a grant by the Bill & Melinda Gates Foundation to develop an easy-to-use, web-based modeling tool for use in determining the cost of goods of pharmaceutical APIs.

Key Points: 
  • BALTIMORE, June 21, 2023 /PRNewswire/ -- Latham BioPharm Group (LBG), part of Sia Partners, has been awarded a grant by the Bill & Melinda Gates Foundation to develop an easy-to-use, web-based modeling tool for use in determining the cost of goods of pharmaceutical APIs.
  • Rapid development of new synthetic pathways, coupled with the ability to consistently evaluate a program's economics, leads to the identification of significant cost reductions and the potential for greater global access from a public health standpoint.
  • We look forward to building on this important work and making these tools more broadly accessible."
  • This project directly aligns with the foundation's public health efforts to enhance global access to patients who often need these products the most.

Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication

Retrieved on: 
Mercredi, octobre 26, 2022
National Institute, Monkeypox virus, Molnupiravir, Ribavirin, Illinois Institute of Technology, Lazzaro Spallanzani National Institute for Infectious Diseases, Omicron, Disease, Risk, Phases of clinical research, Caco-2, IND, Infection, HKEX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, Investigational New Drug, NHC, Permeability, Monkeypox, WHO, Food, World, Orthopoxvirus, Sofosbuvir, Degenerative disease, Mefloquine, Region (Europe), CEO, Patent, IIT Research Institute, BioRxiv, World Health Organization, FDA, COVID-19, Atovaquone, Pharmaceutical industry, Vaccine, Technology

HANGZHOU and SHAOXING, China, Oct. 26, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the Investigational New Drug (IND) application of ASC10, an oral antiviral drug candidate targeting viral polymerase of monkeypox virus, has been filed with the U.S. Food and Drug Administration (FDA).

Key Points: 
  • ASC10 is an orally bioavailable and broad antiviral spectrum double prodrug which has a new and differentiated chemical structure from the single prodrug molnupiravir.
  • Ascletis has filed multiple patent applications globally for ASC10 and its use in viral diseases including monkeypox virus infection.
  • The data from the in vitro antiviral cellular assay with infectious monkeypox virus demonstrated that ASC10-A has potent antiviral activity against monkeypox virus, suggesting that ASC10 has the potential to be an effective treatment of monkeypox virus infection.
  • This IND filing of ASC10 for monkeypox in the U.S. will further broaden Ascletis' pipeline portfolio in viral diseases, and may provide a solution to monkeypox virus infections."

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients

Retrieved on: 
Mercredi, août 3, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, EC50, RNA polymerase II, Severe acute respiratory syndrome coronavirus 2, Phases of clinical research, Omicron, Food, Trial of the century, Molnupiravir, CEO, Tablet, NASH, Degenerative disease, Patent, CHB, COVID-19, Safety, NHC, PBC, RNA-dependent RNA polymerase, Primary biliary cholangitis, Clinical trial, OBI Pharma, Inc., Hong Kong Stock Exchange, FDA, Acne, Patient, Pharmacokinetics, Permeability, Caco-2, HKEX, Fatty liver disease, RNA, IND, Pharmaceutical industry, Delta

HANGZHOU and SHAOXING, China, Aug. 3, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ASC10, an oral drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19, to conduct the Phase Ib clinical trial in mild-to-moderate COVID-19 patients. Ascletis will immediately initiate the clinical trial in patients to collect ASC10's clinical safety, pharmacokinetics and preliminary efficacy data.

Key Points: 
  • Ascletis will immediately initiate the clinical trial in patients to collect ASC10's clinical safety, pharmacokinetics and preliminary efficacy data.
  • ASC10 is an orally bioavailable double prodrug which has a new and differentiated chemical structure from the single prodrug molnupiravir.
  • ASC10 oral tablet formulation for the clinical study was developed with in-house proprietary technology of Ascletis.
  • FDA recommended that Ascletis directly conduct the first clinical study of ASC10 in mild-to-moderate COVID-19 patients rather than in healthy subjects.

Fosun International's FTSE Russell ESG Rating Upgraded and Becomes First-time Constituent of FTSE4Good Index Series

Retrieved on: 
Jeudi, juin 23, 2022
Carbon, MSCI, WHO, Medicines Patent Pool, Happiness, Temperature, Ritonavir, Director, Biophysical environment, Intelligence, Molnupiravir, World Health Organization, Philosophy, Non-executive director, Group, United Kingdom, BioNTech, SPAQ, Social, Artesunate, Fosun Pharma, Disease, Carbon neutrality, Paris, Board, AA, Climate change, Industry, Forbes Global 2000, COVID-19, Forbes, FTSE4Good Index, Sustainability Accounting Standards Board, Patient, Social Security Government Pension Offset, ESG, Multimedia, Paris Agreement, Hong Kong Stock Exchange, Company, Corruption, HKEX, FTSE Russell, MPP, Pfizer, SMC, Malaria, Identity, Management, Renewable energy, Pharmaceutical industry, Merck, Health, Fosun International

Fosun International's FTSE Russell ESG rating has improved for two consecutive years, outperforming the industry average, and has been included in the FTSE4Good Index Series for the first time.

Key Points: 
  • Fosun International's FTSE Russell ESG rating has improved for two consecutive years, outperforming the industry average, and has been included in the FTSE4Good Index Series for the first time.
  • In order to ensure the smooth and continuous progress of ESG work, Fosun has established a top-down and long-term mechanism for ESG improvement.
  • Launched in 2001, the FTSE4Good Index Series is the first index series to measure the performance of companies that meet globally recognized corporate responsibility standards.
  • Fosun International ranks No.589 on the 2022 Forbes Global 2000 List, with a MSCI ESG rating of AA.

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

Retrieved on: 
Jeudi, avril 28, 2022
Mpro, Solution, Program, USAMRIID, Vaccine, CEO, Biotechnology, Percussion section, Fujifilm, Infection, Health, MD, Protease, Multimedia, Research, View, Digital imaging, United States Department of Defense, Hand, Risk, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Molnupiravir, Favipiravir

The combination will include one of Healion Bio's protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan.

Key Points: 
  • The combination will include one of Healion Bio's protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan.
  • Dr. Sina Bavari, co-founder of Healion Bio, noted "Highly contagious pathogens can rarely be stopped by testing, vaccines, and hospital therapeutics alone.
  • We are working with FUJIFILM Toyama to benefit from their decades of experience in oral antivirals."
  • For more information, please visit: holdings.fujifilm.com
    Healion Bio, Inc., Frederick, MD, is a biotechnology development company developing the next generation of antiviral compounds.

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

Retrieved on: 
Jeudi, avril 28, 2022
Mpro, Solution, Program, USAMRIID, Vaccine, CEO, Biotechnology, Percussion section, Fujifilm, Infection, Health, MD, Protease, Research, Digital imaging, United States Department of Defense, Hand, Risk, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Molnupiravir, Favipiravir

The combination will include one of Healion Bio's protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan.

Key Points: 
  • The combination will include one of Healion Bio's protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan.
  • Dr. Sina Bavari, co-founder of Healion Bio, noted "Highly contagious pathogens can rarely be stopped by testing, vaccines, and hospital therapeutics alone.
  • We are working with FUJIFILM Toyama to benefit from their decades of experience in oral antivirals."
  • For more information, please visit: holdings.fujifilm.com
    Healion Bio, Inc., Frederick, MD, is a biotechnology development company developing the next generation of antiviral compounds.

COVID-19 Oral Antiviral Medications Now Available at Most Rite Aid Locations

Retrieved on: 
Mercredi, avril 27, 2022
Pharmaceutical, Medical Supplies, General Health, Health, Specialty, Infectious Diseases, Convenience Store, Retail, Family, Prescription, Rite Aid, Rite, COVID-19, Pharmacy, Vaccination, NYSE, Post-exposure prophylaxis, COVID-19 vaccine, Aid, FDA, Disease, COVID, RAD, Hospital, Molnupiravir, Pharmaceutical industry, Elixir

Rite Aid continues to be a vital resource for our communities as we help customers navigate the COVID pandemic, and we are proud to now have these medications widely available across our footprint, said Karen Staniforth, Chief Pharmacy Officer at Rite Aid.

Key Points: 
  • Rite Aid continues to be a vital resource for our communities as we help customers navigate the COVID pandemic, and we are proud to now have these medications widely available across our footprint, said Karen Staniforth, Chief Pharmacy Officer at Rite Aid.
  • The COVID-19 oral antiviral treatments are available to individuals who test positive, and are within five days of symptom onset, and at high risk for severe COVID-19.
  • Most Rite Aid locations will have one or the other oral antiviral medication available.
  • Customers can visit the Rite Aid store locator at riteaid.com to search locations and their prescription pick-up and delivery services.

COVID-19 Anti-Viral Medication Now Available at All Stop & Shop Pharmacies in New York

Retrieved on: 
Jeudi, avril 7, 2022
Risk, Stop & Shop, Pharmacy, Stop, Hunger, Â, Medicare (United States), CDC, Medicare Part D, Research, Ageing, Shop, Pharmacist, Immunodeficiency, Safety, Calendar, COVID-19, GLOBE, Delhaize Group, Medicare, COVID-19 vaccine, COVID, FDA, Patient, Vaccine, Pharmaceutical industry, Molnupiravir

Once prescribed, Stop & Shop encourages the infected individual to stay home and send a trusted family member or friend to pick up the prescription.

Key Points: 
  • Once prescribed, Stop & Shop encourages the infected individual to stay home and send a trusted family member or friend to pick up the prescription.
  • For everyones health and safety, Stop & Shop associates will also be available to deliver the prescription to customers vehicles via curbside delivery in the stores parking lot.
  • Stop & Shop customers can choose how and where they want to shop - whether in-store or online for delivery or same day pickup.
  • The Stop & Shop Supermarket Company LLC is an Ahold Delhaize USA Company and employs 58,000 associates and operates more than 400 stores throughout Massachusetts, Connecticut, Rhode Island, New York and New Jersey.

Altesa BioSciences Announces Scientific Advisory Board

Retrieved on: 
Lundi, février 28, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Princeton University Department of Chemistry, RNA, Drug development, COVID-19, Virology, GA, Gilead Sciences, Distinguishing, Coronavirus Scientific Advisory Board (Turkey), Chronic obstructive pulmonary disease, Department, HIV, Division, Therapy, Rhinovirus, Partnership, Board, University of North Carolina, University, Emory University School of Medicine, Safety, MS, Critical Care Medicine (journal), Drug discovery, Pulmonology, Collaboration, CEO, Emory University, Director, Chapel Hill, DSMB, Critical care, SAB, Neurosurgery, DRIVE, International Advisory and Monitoring Board, Patient, Doctor of Philosophy, Orthornavirae, Physician, NIH, Infection, FDA, COPD, Emtricitabine, Pharmaceutical industry, Pediatrics, Pharmacology, Medicine, Vaxart, Microbiology, Molnupiravir, Health, Enterovirus, MD

Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel anti-viral drugs against common respiratory viruses and global viral threats, today announced the inaugural members of its Scientific Advisory Board (SAB).

Key Points: 
  • Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel anti-viral drugs against common respiratory viruses and global viral threats, today announced the inaugural members of its Scientific Advisory Board (SAB).
  • Altesa BioSciences, Inc is a biopharmaceutical company based in Atlanta, GA focused on developing antivirals to addresses diseases of global importance.
  • In July 2021, Altesa in-licensed Vapendavir, a Phase 2 antiviral broadly active against enteroviruses, including rhinovirus, from Vaxart.
  • Altesa intends to progress Vapendavir into Phase 2b trial in the coming months for treatment of rhinovirus in at-risk populations.